Last €2.67 EUR
Change Today -0.04 / -1.48%
Volume 822.3K
As of 11:38 AM 04/23/14 All times are local (Market data is delayed by at least 15 minutes).

zeltia sa (ZEL) Snapshot

Open
€2.77
Previous Close
€2.71
Day High
€2.78
Day Low
€2.64
52 Week High
01/15/14 - €3.08
52 Week Low
04/29/13 - €1.44
Market Cap
593.3M
Average Volume 10 Days
835.0K
EPS TTM
€-2.48
Shares Outstanding
222.2M
EX-Date
07/15/11
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ZELTIA SA (ZEL)

Related News

No related news articles were found.

zeltia sa (ZEL) Related Businessweek News

No Related Businessweek News Found

zeltia sa (ZEL) Details

Zeltia, S.A., a biopharmaceutical company, is engaged in the research, development, production, and marketing of various types of bioactive products of marine origin for application in oncology. It is also involved in the development and marketing of biopharmaceutical applications, diagnosis, and related services; and research, development, production, and sale of products with therapeutic activity based on reducing or silencing gene expression and pharmaceutical derivatives of same in a range of formulations. Its products include Yondeli, a marketed product for the treatment of relapsed ovarian cancer and soft tissue sarcoma; Aplidi, which is in Phase III clinical trials for the treatment of multiple myeloma; Zalypsi that is in Phase II clinical trials for the treatment of ovarian cancer and multiple myeloma; PM01183, which is in Phase II clinical trials for the treatment of breast cancer and leukemia; PM060184 that is in Phase I clinical trials for the treatment of solid tumors; SYL040012, which is in Phase II clinical trials for the treatment of glaucoma and dry eye syndrome; and DNA diagnosis and analysis kits. The company is also involved in the manufacture and sale of wood and metal protective and decorative products, paints, and other related products; manufacture and marketing of domestic and industrial insecticides and air fresheners; manufacture and sale of automatic aerosol dispensers under the Copyrmatic brand; and production of products for ecological farming. In addition, it provides services for treating and protecting wood, and repairing and preserving structures, as well as insect control and disinfection. Zeltia, S.A. was founded in 1939 and is headquartered in Madrid, Spain.

Founded in 1939

zeltia sa (ZEL) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

zeltia sa (ZEL) Key Developments

Zeltia SA Presents at European Smallcap Event, Apr-07-2014

Zeltia SA Presents at European Smallcap Event, Apr-07-2014 . Venue: Pullman Tour Eiffel, Paris, France.

The Zeltia Group Reports Earnings Results for the Fourth Quarter and Year Ended December 31, 2013

The Zeltia Group reported earnings results for the fourth quarter and year ended December 31, 2013. For the period, the reported loss attributable to equity-holders of the parent company of EUR 2.77 million, compared to a loss attributable to equity-holders of the parent company of EUR 1.95 million for the same quarter ended December 31, 2012. Total revenue was EUR 34.54 million, compared to EUR 29.86 million for the same quarter ended December 31, 2012. Income attributable to equity-holders of the parent company for the year ended December 31, 2013 was EUR 11.32 million, compared to EUR 6.59 million for the year ended December 31, 2012. Total revenue for the year ended December 31, 2013 was EUR 164.68 million, compared to EUR 161.78 million for the year ended December 31, 2012.

Zeltia SA Reports Earnings Results for the Year Ended December 31, 2013

Zeltia SA reported earnings results for the year ended December 31, 2013. For the year, the company reported EBITDA of EUR 23.8 million increased by 16.6%. The groups operating cash flow totaled EUR 16.1 million against EUR 6.6 million a year ago. Net attributable profit of EUR 11.3 million against EUR 6.5 million a year ago. Revenues totaled EUR 142 million against EUR 138 million a year ago, of which EUR 79 million were generated from the biopharmaceutical segment and EUR 62 million from consumer chemicals. EBITDA amounted to EUR 23.8 million against EUR 20.4 million a year ago. Net sales of Yondelis increased by 10% in 2013. The group also said it managed to strengthen its leverage and debt coverage ratio, as higher cash flow and results reduced total net debt by nearly 20%.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ZEL:SM €2.67 EUR -0.04

ZEL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ZEL.
View Industry Companies
 

Industry Analysis

ZEL

Industry Average

Valuation ZEL Industry Range
Price/Earnings 50.8x
Price/Sales 4.2x
Price/Book 11.3x
Price/Cash Flow 53.4x
TEV/Sales 3.4x
 | 

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ZELTIA SA, please visit www.zeltia.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.